Abstract Number: 1522 • 2014 ACR/ARHP Annual Meeting
Impact of Sarilumab on Health Related Quality of Life (HRQoL), Fatigue, and Sleep in Rheumatoid Arthritis Patients at Week 24 – Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study
Background/Purpose: Sarilumab, a fully human monoclonal antibody directed against the IL-6 receptor, demonstrated efficacy in the phase 3 part of the RA-MOBILITY study (NCT01061736) in…Abstract Number: 1482 • 2014 ACR/ARHP Annual Meeting
Response of Patient Reported Symptoms of Stiffness and Pain during the Day from Adding Low-Dose Delayed-Release (DR) Prednisone to Stable DMARD Therapy over 12 Weeks in Patients with Moderate Rheumatoid Arthritis (RA)
Background/Purpose: RA patients experience stiffness which impacts their daily lives. Although this patient reported symptom was dropped from the RA classification criteria there is growing…Abstract Number: 942 • 2014 ACR/ARHP Annual Meeting
ACR/EULAR Remission in RA patients in Clinical Practice – Does Substitution of Patient Global with Pain Score Change Remission Rates? Data from the Danish Danbio Registry
Background/Purpose: Modern treatment strategy in RA aims at remission. In 2011, new ACR/EULAR remission criteria were published for patients with RA. Of four Boolean criteria,…Abstract Number: 356 • 2014 ACR/ARHP Annual Meeting
The Rheumatoid Arthritis Impact of Disease Score Is Associated with Disease Activity By Clinical, Laboratory and Ultrasonographic Measures: Validation in an inception Cohort of DMARD naïve Patients with Rheumatoid Arthritis
Background/Purpose: The Rheumatoid arthritis impact of disease (RAID) score is a relatively new patient-derived composite score assessing the seven most important domains of the impact…
ACR Meeting Abstracts